Jefferies analyst Eun Yang raised her price target for BioMarin to $125 saying that with multiple clinical catalysts in 2019-2020 supporting potential regulatory approval of three new products, she expects the stock to move higher. If pivotal trials for the three new products, valrox in hemophilia A gene therapy, vosoritide in achondroplasia, and BMN-250 in Sanfilippo B syndrome, are successful, the analyst sees a fair value for BioMarin at $140 per share. The stock's current risk/reward is favorable, particularly with currently marketed products providing a $90 per share "valuation floor," Yang tells investors in a research note. She keeps a Buy rating on BioMarin.